By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Celator Pharmaceuticals, Inc. 

303B College Road East

Princeton  New Jersey  08540  U.S.A.
Phone: 609-243-0123 Fax: 609-243-0202


SEARCH JOBS








Company News
Celator Pharmaceuticals, Inc. To Present On Fixed-Ratio Nanomedicines At The 2015 Controlled Release Society Annual Meeting 7/28/2015 11:55:53 AM
Celator Pharmaceuticals, Inc. Announces Start Of Clinical Study Of CPX-351 In Acute Myeloid Leukemia Patients At High Risk For Induction Mortality 7/14/2015 7:00:50 AM
Celator Pharmaceuticals, Inc. To Host Analyst And Investor Day On July 16, 2015 7/7/2015 7:41:17 AM
Celator Pharmaceuticals, Inc. Release: The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated With The Phase 3 Study Of CPX-351 In High Risk (Secondary) AML 6/29/2015 8:45:25 AM
The Leukemia & Lymphoma Society Applauds Encouraging Data Released By Celator Pharmaceuticals, Inc. From Its Phase 3 Clinical Study Of CPX-351 For High-Risk Acute Myeloid Leukemia Patients 6/24/2015 9:42:50 AM
Celator Pharmaceuticals, Inc. Announces Positive Induction Response Results From Phase 3 Study Of CPX-351 In Patients With High-Risk (Secondary) Acute Myeloid Leukemia 6/24/2015 6:35:48 AM
Celator Pharmaceuticals, Inc. To Present At The JMP Securities Life Sciences Conference 2015 6/18/2015 7:24:19 AM
Celator Pharmaceuticals, Inc. Announces Expansion of Clinical Study In Patients With Untreated Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) At High-Risk Of Treatment-Related Mortality 6/8/2015 6:38:30 AM
Celator Pharmaceuticals, Inc. To Present At The 2015 BIO International Convention 6/4/2015 7:01:56 AM
Celator Pharmaceuticals, Inc. Announces Enrollment Is Complete In CPX-351 Phase 2 Study 6/3/2015 9:36:44 AM
12345678910...
//-->